<code id='560ADB2097'></code><style id='560ADB2097'></style>
    • <acronym id='560ADB2097'></acronym>
      <center id='560ADB2097'><center id='560ADB2097'><tfoot id='560ADB2097'></tfoot></center><abbr id='560ADB2097'><dir id='560ADB2097'><tfoot id='560ADB2097'></tfoot><noframes id='560ADB2097'>

    • <optgroup id='560ADB2097'><strike id='560ADB2097'><sup id='560ADB2097'></sup></strike><code id='560ADB2097'></code></optgroup>
        1. <b id='560ADB2097'><label id='560ADB2097'><select id='560ADB2097'><dt id='560ADB2097'><span id='560ADB2097'></span></dt></select></label></b><u id='560ADB2097'></u>
          <i id='560ADB2097'><strike id='560ADB2097'><tt id='560ADB2097'><pre id='560ADB2097'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:focus    Page View:35951
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In